Infectious Disease Project Organ-Based Infections: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 168: | Line 168: | ||
<h4>Myocarditis, viral {{ID-returntotop-organ}}</h4> | <h4>Myocarditis, viral {{ID-returntotop-organ}}</h4> | ||
<h3>Pericarditis</h3> | |||
<h4>Pericarditis, bacterial {{ID-returntotop-organ}}</h4> | <h4>Pericarditis, bacterial {{ID-returntotop-organ}}</h4> | ||
Revision as of 20:59, 2 June 2015
WikiDoc Infectious Disease Project — Organ-Based Infections
Cardiovascular ● Central Nervous System ● Head and Neck ● Eye ● Upper Respiratory Tract ● Lower Respiratory Tract ● Gastrointestinal and Intraabdominal ● Genitourinary ● Musculoskeletal ● Skin and Soft Tissues ● Systemic
The unnamed parameter 2= is no longer supported. Please see the documentation for {{columns-list}}.
3Cardiovascular
Aortitis, infectious ⇧ Return to Top ⇧
Cardiovascular implantable electronic device infections ⇧ Return to Top ⇧
Endocarditis
Endocarditis, prophylaxis ⇧ Return to Top ⇧
Endocarditis, treatment ⇧ Return to Top ⇧
- Infective endocarditis[1]
- Culture-negative endocarditis
- Culture-negative, native valve endocarditis
- Preferred regimen: Ampicillin-sulbactam 12 g/24h IV q6h 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 4–6 weeks
- Alternative regimen: Vancomycin 30 mg/kg/24h IV q12h for 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 4–6 weeks AND Ciprofloxacin 1000 mg/24h PO or 800 mg/24h IV q12h for 4–6 weeks
- Pediatric dose: Ampicillin-sulbactam 300 mg/kg/24h IV q4–6h; Gentamicin 3 mg/kg/24h IV/IM q8h; Vancomycin 40 mg/kg/24h q8–12h; Ciprofloxacin 20–30 mg/kg/24h IV/PO q12h
- Culture-negative, prosthetic valve endocarditis (early, ≤ 1 year)
- Preferred regimen : Vancomycin 30 mg/kg/24h IV q12h for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 2 weeks AND Cefepime 6 g/24h IV q8h for 6 weeks AND Rifampin 900 mg/24h PO/IV q8h for 6 weeks
- Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h; Gentamicin 3 mg/kg/24h IV/IM q8h; Cefepime 150 mg/kg/24h IV q8h; Rifampin 20 mg/kg/24h PO/IV q8h
- Culture-negative, prosthetic valve endocarditis (late, > 1 year)
- Preferred regimen: Ampicillin-sulbactam 12 g/24h IV q6h 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 6 weeks
- Alternative regimen: Vancomycin 30 mg/kg/24h IV q12h for 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 6 weeks AND Ciprofloxacin 1000 mg/24h PO or 800 mg/24h IV q12h for 6 weeks
- Pediatric dose: Ampicillin-sulbactam 300 mg/kg/24h IV q4h; Gentamicin 3 mg/kg/24h IV/IM q8h; Vancomycin 40 mg/kg/24h q8–12h; Ciprofloxacin 20–30 mg/kg/24h IV/PO q12h
- Culture-negative, prosthetic valve endocarditis (early, ≤ 1 year)
- Preferred regimen: Ampicillin-sulbactam 12 g/24h IV q6h 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 4–6 weeks AND Rifampin 900 mg/24h PO/IV q8h for 6 weeks
- Alternative regimen: Vancomycin 30 mg/kg/24h IV q12h for 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 4–6 weeks AND Ciprofloxacin 1000 mg/24h PO or 800 mg/24h IV q12h for 4–6 weeks AND Rifampin 900 mg/24h PO/IV q8h for 6 weeks
- Pediatric dose: Ampicillin-sulbactam 300 mg/kg/24h IV q4–6h; Gentamicin 3 mg/kg/24h IV/IM q8h; Vancomycin 40 mg/kg/24h IV q8–12h; Cefepime 150 mg/kg/24h IV q8h; Rifampin 20 mg/kg/24h PO/IV q8h
- Pathogen-directed antimicrobial therapy
- Bartonella
- Suspected Bartonella endocarditis
- Preferred regimen : Ceftriaxone sodium 2 g/24h IV/IM in 1 dose for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 2 weeks ± Doxycycline 200 mg/kg/24h IV/PO q12h for 6 weeks
- Pediatric dose: Ceftriaxone 100 mg/kg/24h IV/IM once daily; Gentamicin 3 mg/kg/24h IV/IM q8h; Doxycycline 2–4 mg/kg/24h IV/PO q12h; Rifampin 20 mg/kg/24h PO/IV q12h
- Documented Bartonella endocarditis
- Preferred regimen: Doxycycline 200 mg/24h IV or PO q12h for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 2 weeks
- Pediatric dose: Ceftriaxone 100 mg/kg/24h IV/IM once daily; Gentamicin 3 mg/kg/24h IV/IM q8h; Doxycycline 2–4 mg/kg/24h IV/PO q12h; Rifampin 20 mg/kg/24h PO/IV q12h
- Enterococcus
- Endocarditis caused by enterococcal strains susceptible to penicillin, gentamicin, and vancomycin
- Preferred regimen : Ampicillin 12 g/24h IV q4h for 4–6 weeks OR Penicillin G 18–30 million U/24h IV either continuously or q4h for 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 4–6weeks
- Alternative regimen : Vancomycin 30 mg/kg/24h IV q12h for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 6 weeks
- Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h; Gentamicin 3 mg/kg/24h IV/IM q8h
- Endocarditis caused by enterococcal strains susceptible to penicillin, streptomycin, and vancomycin and resistant to gentamicin
- Preferred regimen : Ampicillin 12 g/24h IV q4h for 4–6 weeks OR Penicillin G 24 million U/24h IV continuously or q4h for 4–6 weeks AND Streptomycin 15 mg/kg/24h IV/IM q12h for 4–6 weeks
- Alternative regimen : Vancomycin 30 mg/kg/24h IV q12h for 6 weeks AND Streptomycin 15 mg/kg/24h IV/IM q12h for 6 weeks
- Pediatric dose: Ampicillin 300 mg/kg/24h IV q4–6h; Penicillin 300 000 U/kg/24h IV q4–6h; Streptomycin 20–30 mg/kg/24h IV/IM q12h; Vancomycin 40 mg/kg/24h IV q8–12h; Streptomycin 20–30 mg/kg/24h IV/IM q12h
- Endocarditis caused by enterococcal strains resistant to penicillin and susceptible to aminoglycoside and vancomycin
- β-Lactamase–producing strain
- Preferred regimen: Ampicillin-sulbactam 12 g/24h IV q6h for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 6 weeks
- Alternative regimen : Vancomycin 30 mg/kg/24h IV q12h for 6 weeks
- Pediatric dose: Ampicillin-sulbactam 300 mg/kg/24h IV q6h; Gentamicin 3 mg/kg/24h IV/IM q8h
- Intrinsic penicillin resistance
- Preferred regimen: Vancomycin 30 mg/kg/24h IV q12h for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 6 weeks
- Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h; Gentamicin 3 mg/kg/24h IV/IM q8h
- Endocarditis caused by enterococcal strains resistant to penicillin, gentamicin, and vancomycin
- Enterococcus faecium
- Preferred regimen : Linezolid 1200 mg/24h IV/PO q12h for ≥ 8 weeks OR Quinupristin-Dalfopristin 22.5 mg/kg/24h IV q8h for 8 weeks
- Enterococcus faecalis
- Preferred regimen : Imipenem/cilastatin 2 g/24h IV q6h for ≥ 8 weeks AND Ampicillin 12 g/24h IV q4h for ≥ 8 weeks OR Ceftriaxone sodium 4 g/24h IV/IM q12h for ≥ 8 weeks AND Ampicillin 12 g/24h IV q4h for ≥ 8 weeks
- Pediatric dose: Linezolid 30 mg/kg/24h IV/PO q8h; Quinupristin-Dalfopristin 22.5 mg/kg/24h IV q8h; Imipenem/cilastatin 60–100 mg/kg/24h IV q6h; Ampicillin 300 mg/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM q12h
- HACEK organisms
- Endocarditis caused by Haemophilus, Aggregatibacter (Actinobacillus), Cardiobacterium, Eikenella corrodens, or Kingella
- Preferred regimen : Ceftriaxone sodium 2 g/24h IV/IM in 1 dose for 4 weeks OR Ampicillin 12 g/24h IV q6h for 4 weeks OR Ciprofloxacin 1000 mg/24h PO or 800 mg/24h IV q12h for 4 weeks
- Pediatric dose: Ceftriaxone 100 mg/kg/24h IV/IM once daily; Ampicillin-sulbactam 300 mg/kg/24h IV divided into 4 or 6 equally divided doses; Ciprofloxacin 20–30 mg/kg/24h IV/PO q12h
- Staphylococcus
- Native valve endocarditis caused by oxacillin-susceptible staphylococci
- Preferred regimen (1): Nafcillin or Oxacillin 12 g/24h IV q4–6h for 6 weeks ± Gentamicin 3 mg/kg/24h IV/IM q8–12h for 3–5 days
- Preferred regimen (2): Cefazolin 6 g/24h IV q8h for 6 weeks ± Gentamicin 3 mg/kg/24h IV/IM q8–12h for 3–5 days
- Pediatric dose: Nafcillin or Oxacillin 200 mg/kg/24h IV q4–6h; Gentamicin 3 mg/kg/24h IV/IM q8h; Cefazolin 100 mg/kg/24h IV q8h; Gentamicin 3 mg/kg/24h IV/IM q8h
- Native valve endocarditis caused by oxacillin-resistant staphylococci
- Preferred regimen: Vancomycin 30 mg/kg/24h IV q12h for 6 weeks
- Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h
- Prosthetic valve endocarditis caused by oxacillin-susceptible staphylococci
- Preferred regimen: Nafcillin or Oxacillin 12 g/24h IV q4h for ≥ 6 weeks AND Rifampin 900 mg/24h IV/PO q8h for ≥ 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8–12h for 2 weeks
- Pediatric dose: Nafcillin or Oxacillin 200 mg/kg/24h IV q4–6h; Rifampin 20 mg/kg/24h IV/PO q8h; Gentamicin 3 mg/kg/24h IV/IM q8h
- Prosthetic valve endocarditis caused by oxacillin-resistant staphylococci
- Preferred regimen: Vancomycin 30 mg/kg 24 h q12h for ≥ 6 weeks AND Rifampin 900 mg/24h IV/PO q8h for ≥ 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8–12h for 2 weeks
- Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h; Rifampin 20 mg/kg/24h IV/PO q8h (up to adult dose); Gentamicin 3 mg/kg/24h IV or IM q8h
- Viridans group streptococci and Streptococcus bovis
- Native valve endocarditis caused by highly penicillin-susceptible viridans group streptococci and Streptococcus bovis (MIC ≤ 0.12 μg/mL)
- Preferred regimen: Penicillin G 12–18 million U/24h IV either continuously or q4–6h for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks
- Alternative regimen (1): (Penicillin G 12–18 million U/24h IV either continuously or q4h for 2 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 2 weeks) AND Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
- Alternative regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 4 weeks
- Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
- Native valve endocarditis caused by relatively penicillin-resistant viridans group streptococci and Streptococcus bovis (MIC > 0.12 to ≤ 0.5 μg/mL)
- Preferred regimen (1): (Penicillin G 24 million U/24h IV either continuously or q4–6h for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks) AND Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
- Preferred regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 4 weeks
- Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
- Prosthetic valve endocarditis caused by highly penicillin-susceptible viridans group streptococci and Streptococcus bovis (MIC ≤ 0.12 μg/mL)
- Preferred regimen (1): (Penicillin G 24 million U/24h IV either continuously or q4–6h for 6 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 6 weeks) ± Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
- Preferred regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 6 weeks
- Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
- Prosthetic valve endocarditis caused by relatively penicillin-resistant viridans group streptococci and Streptococcus bovis (MIC > 0.12 μg/mL)
- Preferred regimen (1): (Penicillin G 24 million U/24h IV either continuously or q4–6h for 6 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 6 weeks) AND Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
- Preferred regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 6 weeks
- Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
Mediastinitis, acute ⇧ Return to Top ⇧
Mycotic aneurysm ⇧ Return to Top ⇧
- Empiric antimicrobial therapy[2]
- Preferred regimen: Vancomycin 2 g/day IV divided q6-12h targeting trough concentration of 15-20 μg/mL for 6 weeks (for critically ill patient, start with a loading dose of 25 mg/kg followed by 15 mg/kg q12h) AND (Ceftriaxone 2 g IV q24h for 6 weeks OR Piperacillin-Tazobactam 3.375 g IV q6h for 6 weeks OR Ciprofloxacin 400 mg IV q12h for 6 weeks)
- Alternative regimen: Consider substituting Daptomycin for Vancomycin. Consider Cefepime, Imipenem-Cilastatin, Meropenem, or Ertapenem for Gram-negative bacteria.
Myocarditis
Lyme carditis ⇧ Return to Top ⇧
- Lyme carditis, adult[3]
- Parenteral regimen
- Preferred regimen: Ceftriaxone 2 g IV q24h for 14 (14–21) days
- Alternative regimen: Cefotaxime 2 g IV q8h for 14 (14–21) days OR Penicillin G 18–24 million U/day IV q4h for 14 (14–21) days
- Oral regimen
- Preferred regimen: Amoxicillin 500 mg tid for 14 (14–21) days OR Doxycycline 100 mg bid for 14 (14–21) days OR Cefuroxime 500 mg bid for 14 (14–21) days
- Alternative regimen: Azithromycin 500 mg PO qd for 7–10 days OR Clarithromycin 500 mg PO bid for 14–21 days (if the patient is not pregnant) OR Erythromycin 500 mg PO qid for 14–21 days
- Note (1): Parenteral regimen is recommended at the start of therapy for patients who have been hospitalized for cardiac monitoring; oral regimen may be substituted to complete a course of therapy or to treat ambulatory patients.
- Note (2): A temporary pacemaker may be required for patients with advanced heart block.
- Note (3): Patients treated with macrolides should be closely observed to ensure resolution of the clinical manifestations.
- Lyme carditis, pediatric[4]
- Parenteral regimen
- Preferred regimen: Ceftriaxone 50–75 mg/kg IV q24h (maximum, 2 g) for 14 (14–21) days
- Alternative regimen: Cefotaxime 150–200 mg/kg/day IV q6–8h (maximum, 6 g per day) for 14 (14–21) days OR Penicillin G 200,000–400,000 U/kg/day IV q4h (not to exceed 18–24 million U per day) for 14 (14–21) days
- Oral regimen
- Preferred regimen: Amoxicillin 50 mg/kg/day PO tid (maximum, 500 mg per dose) for 14 (14–21) days OR Doxycycline (for children aged ≥ 8 years) 4 mg/kg/day PO bid (maximum, 100 mg per dose) for 14 (14–21) days OR Cefuroxime 30 mg/kg/day PO bid (maximum, 500 mg per dose) for 14 (14–21) days
- Alternative regimen: Azithromycin 10 mg/kg/day (maximum of 500 mg per day) for 7–10 days OR Clarithromycin 7.5 mg/kg PO bid (maximum of 500 mg per dose) for 14–21 days OR Erythromycin 12.5 mg/kg PO qid (maximum of 500 mg per dose) for 14–21 days
- Note (1): Parenteral regimen is recommended at the start of therapy for patients who have been hospitalized for cardiac monitoring; oral regimen may be substituted to complete a course of therapy or to treat ambulatory patients.
- Note (2): A temporary pacemaker may be required for patients with advanced heart block.
- Note (3): Patients treated with macrolides should be closely observed to ensure resolution of the clinical manifestations.
Myocarditis, viral ⇧ Return to Top ⇧
Pericarditis
Pericarditis, bacterial ⇧ Return to Top ⇧
Pericarditis, fungal ⇧ Return to Top ⇧
Pericarditis, tuberculous ⇧ Return to Top ⇧
Pericarditis, viral ⇧ Return to Top ⇧
Rheumatic fever, primary prophylaxis ⇧ Return to Top ⇧
Rheumatic fever, secondary prophylaxis ⇧ Return to Top ⇧
Septic pelvic vein thrombophlebitis ⇧ Return to Top ⇧
Central Nervous System
Brain abscess ⇧ Return to Top ⇧
Cerebrospinal fluid shunt infection ⇧ Return to Top ⇧
Encephalitis ⇧ Return to Top ⇧
Epidural abscess ⇧ Return to Top ⇧
Lyme neuroborreliosis ⇧ Return to Top ⇧
Meningitis, bacterial ⇧ Return to Top ⇧
Meningitis, MRSA ⇧ Return to Top ⇧
Meningitis, tuberculous ⇧ Return to Top ⇧
Septic thrombosis of cavernous or dural venous sinus ⇧ Return to Top ⇧
Septic thrombosis of cavernous or dural venous sinus, MRSA ⇧ Return to Top ⇧
Subdural empyema ⇧ Return to Top ⇧
Head and Neck
Anthrax, oropharyngeal ⇧ Return to Top ⇧
Buccal cellulitis ⇧ Return to Top ⇧
Cervico-facial actinomycosis ⇧ Return to Top ⇧
Deep neck infection ⇧ Return to Top ⇧
Facial cellulitis ⇧ Return to Top ⇧
Mastoiditis ⇧ Return to Top ⇧
Mastoiditis, Acute ⇧ Return to Top ⇧
Mastoiditis, Chronic ⇧ Return to Top ⇧
Odontogenic infection ⇧ Return to Top ⇧
Orbital cellulitis ⇧ Return to Top ⇧
Oropharyngeal candidiasis ⇧ Return to Top ⇧
Otitis externa ⇧ Return to Top ⇧
Otitis externa, Chronic ⇧ Return to Top ⇧
Otitis externa, Fungal ⇧ Return to Top ⇧
Otitis externa, Malignant ⇧ Return to Top ⇧
Otitis externa, Swimmer's ear ⇧ Return to Top ⇧
Otitis media ⇧ Return to Top ⇧
Otitis media, Acute ⇧ Return to Top ⇧
Otitis media, Post-intubation ⇧ Return to Top ⇧
Otitis media, Prophylaxis ⇧ Return to Top ⇧
Otitis media, Treatment failure ⇧ Return to Top ⇧
Parotitis ⇧ Return to Top ⇧
Eye
Conjunctivitis ⇧ Return to Top ⇧
Blepharitis ⇧ Return to Top ⇧
Endophthalmitis, bacterial ⇧ Return to Top ⇧
Endophthalmitis, candidal ⇧ Return to Top ⇧
Endophthalmitis, chronic ⇧ Return to Top ⇧
Endophthalmitis, mold ⇧ Return to Top ⇧
Endophthalmitis, post-cataract surgery, acute ⇧ Return to Top ⇧
Endophthalmitis, post-cataract surgery, chronic ⇧ Return to Top ⇧
Endophthalmitis, post-tramatic ⇧ Return to Top ⇧
Keratitis, bacterial ⇧ Return to Top ⇧
Keratitis, fungal ⇧ Return to Top ⇧
Keratitis, protozoal ⇧ Return to Top ⇧
Keratitis, viral ⇧ Return to Top ⇧
Ocular syphilis ⇧ Return to Top ⇧
Ocular toxocariasis ⇧ Return to Top ⇧
Ocular toxoplasmosis ⇧ Return to Top ⇧
Ocular tuberculosis ⇧ Return to Top ⇧
Orbital cellulitis ⇧ Return to Top ⇧
Periocular Infection ⇧ Return to Top ⇧
Retinal necrosis, acute, CMV ⇧ Return to Top ⇧
Retinal necrosis, acute, HSV or VZV ⇧ Return to Top ⇧
Retinal necrosis, progressive outer, VZV ⇧ Return to Top ⇧
Retinitis, CMV ⇧ Return to Top ⇧
Stye ⇧ Return to Top ⇧
Uveitis, acute anterior ⇧ Return to Top ⇧
Uveitis, Lyme disease ⇧ Return to Top ⇧
Upper Respiratory Tract
Epiglottitis ⇧ Return to Top ⇧
Jugular vein phlebitis ⇧ Return to Top ⇧
Laryngitis ⇧ Return to Top ⇧
Lemierre's syndrome ⇧ Return to Top ⇧
Ludwig's angina ⇧ Return to Top ⇧
Parapharyngeal space infection ⇧ Return to Top ⇧
Pharyngitis, diphtheria ⇧ Return to Top ⇧
Pharyngitis, streptococcal ⇧ Return to Top ⇧
Sinusitis, Acute ⇧ Return to Top ⇧
Sinusitis, Chronic ⇧ Return to Top ⇧
Sinusitis, Post-intubation ⇧ Return to Top ⇧
Sinusitis, Treatment failure ⇧ Return to Top ⇧
Stomatitis ⇧ Return to Top ⇧
Stomatitis, aphthous ⇧ Return to Top ⇧
Stomatitis, herpetic ⇧ Return to Top ⇧
Submandibular space infection ⇧ Return to Top ⇧
Tonsillitis ⇧ Return to Top ⇧
Ulcerative gingivitis ⇧ Return to Top ⇧
Vincent's angina ⇧ Return to Top ⇧
Lower Respiratory Tract
Acute bacterial exacerbations of chronic bronchitis ⇧ Return to Top ⇧
Bronchiectasis ⇧ Return to Top ⇧
Bronchiolitis ⇧ Return to Top ⇧
Bronchitis ⇧ Return to Top ⇧
Cystic fibrosis ⇧ Return to Top ⇧
Empyema ⇧ Return to Top ⇧
Influenza ⇧ Return to Top ⇧
Inhalational anthrax, Prophylaxis ⇧ Return to Top ⇧
Inhalational anthrax, Treatment ⇧ Return to Top ⇧
Pertussis ⇧ Return to Top ⇧
Pneumonia, Acinetobacter ⇧ Return to Top ⇧
Pneumonia, Actinomycosis ⇧ Return to Top ⇧
Pneumonia, Anaerobes ⇧ Return to Top ⇧
Pneumonia, Aspiration pneumonia ⇧ Return to Top ⇧
Pneumonia, Chlamydophila ⇧ Return to Top ⇧
Pneumonia, community-acquired ⇧ Return to Top ⇧
Pneumonia, concomitant influenza ⇧ Return to Top ⇧
Pneumonia, Cytomegalovirus ⇧ Return to Top ⇧
Pneumonia, Haemophilus Influenza ⇧ Return to Top ⇧
Pneumonia, health care-associated ⇧ Return to Top ⇧
Pneumonia, hospital-acquired ⇧ Return to Top ⇧
Pneumonia, Klebsiella ⇧ Return to Top ⇧
Pneumonia, Legionella ⇧ Return to Top ⇧
Pneumonia, Lung abscess ⇧ Return to Top ⇧
Pneumonia, Meliodosis ⇧ Return to Top ⇧
Pneumonia, Moraxella catarrhalis ⇧ Return to Top ⇧
Pneumonia, Mycoplasma ⇧ Return to Top ⇧
Pneumonia, neutropenic patient ⇧ Return to Top ⇧
Pneumonia, Nocardia ⇧ Return to Top ⇧
Pneumonia, post-influenza ⇧ Return to Top ⇧
Pneumonia, Pseuodomonas ⇧ Return to Top ⇧
Pneumonia, Staphylococcus aureus ⇧ Return to Top ⇧
Pneumonia, Stenotrophomonas ⇧ Return to Top ⇧
Pneumonia, Streptococcus pneumoniae ⇧ Return to Top ⇧
Pneumonia, Tularemia ⇧ Return to Top ⇧
Pneumonia, Yersinia pestis ⇧ Return to Top ⇧
Gastrointestinal and Intraabdominal
Anthrax, gastrointestinal ⇧ Return to Top ⇧
Appendicitis ⇧ Return to Top ⇧
Biliary sepsis ⇧ Return to Top ⇧
Cholangitis ⇧ Return to Top ⇧
Cholecystitis ⇧ Return to Top ⇧
Diverticulitis ⇧ Return to Top ⇧
Esophagitis ⇧ Return to Top ⇧
Hepatic abscess ⇧ Return to Top ⇧
Hepatitis A ⇧ Return to Top ⇧
Hepatitis B ⇧ Return to Top ⇧
Hepatitis C ⇧ Return to Top ⇧
Hepatitis D ⇧ Return to Top ⇧
Hepatitis E ⇧ Return to Top ⇧
Infectious diarrhea ⇧ Return to Top ⇧
Leptospirosis ⇧ Return to Top ⇧
Pancreatitis ⇧ Return to Top ⇧
Peliosis hepatitis ⇧ Return to Top ⇧
Peptic ulcer disease ⇧ Return to Top ⇧
Peritonitis, secondary to bowel perforation ⇧ Return to Top ⇧
Peritonitis, secondary to dialysis ⇧ Return to Top ⇧
Peritonitis, secondary to ruptured appendix ⇧ Return to Top ⇧
Peritonitis, secondary to ruptured diverticula ⇧ Return to Top ⇧
Peritonitis, spontaneous bacterial ⇧ Return to Top ⇧
Post-transplant infected biloma ⇧ Return to Top ⇧
Splenic abscess ⇧ Return to Top ⇧
Tropical sprue ⇧ Return to Top ⇧
Typhlitis ⇧ Return to Top ⇧
Variceal bleeding, prophylaxis ⇧ Return to Top ⇧
Whipple's disease ⇧ Return to Top ⇧
Genitourinary
Asymptomatic bacteriuria ⇧ Return to Top ⇧
Bacterial vaginosis ⇧ Return to Top ⇧
Cervicitis ⇧ Return to Top ⇧
Chancroid ⇧ Return to Top ⇧
Chlamydial infections ⇧ Return to Top ⇧
Chorioamnionitis ⇧ Return to Top ⇧
Cystitis ⇧ Return to Top ⇧
Ectoparasitic infections ⇧ Return to Top ⇧
Epididymitis ⇧ Return to Top ⇧
Genital herpes ⇧ Return to Top ⇧
Gonococcal infections ⇧ Return to Top ⇧
Granuloma Inguinale ⇧ Return to Top ⇧
Human papillomavirus infection ⇧ Return to Top ⇧
Lymphogranuloma venereum ⇧ Return to Top ⇧
Pelvic inflammatory disease ⇧ Return to Top ⇧
Proctocolitis ⇧ Return to Top ⇧
Prostatitis, acute bacterial ⇧ Return to Top ⇧
Prostatitis, chronic bacterial ⇧ Return to Top ⇧
Pyelonephritis ⇧ Return to Top ⇧
Syphilis ⇧ Return to Top ⇧
Urethritis ⇧ Return to Top ⇧
Vulvovaginal candidiasis ⇧ Return to Top ⇧
Musculoskeletal
Bursitis ⇧ Return to Top ⇧
Osteomyelitis, candidal ⇧ Return to Top ⇧
Osteomyelitis, chronic ⇧ Return to Top ⇧
Osteomyelitis, contiguous with vascular insufficiency ⇧ Return to Top ⇧
Osteomyelitis, contiguous without vascular insufficiency ⇧ Return to Top ⇧
Osteomyelitis, diabetic foot ⇧ Return to Top ⇧
Osteomyelitis, foot bone ⇧ Return to Top ⇧
Osteomyelitis, foot puncture wound ⇧ Return to Top ⇧
Osteomyelitis, hematogenous ⇧ Return to Top ⇧
Osteomyelitis, hemoglobinopathy ⇧ Return to Top ⇧
Osteomyelitis, prosthetic joint infection ⇧ Return to Top ⇧
Osteomyelitis, spinal implant ⇧ Return to Top ⇧
Osteomyelitis, sternal ⇧ Return to Top ⇧
Reactive arthritis, post-streptococcal arthritis ⇧ Return to Top ⇧
Reactive arthritis, Reiter's syndrome ⇧ Return to Top ⇧
Septic arthritis, brucellosis ⇧ Return to Top ⇧
Septic arthritis, candidal ⇧ Return to Top ⇧
Septic arthritis, gonococcal ⇧ Return to Top ⇧
Septic arthritis, Gram-negative bacilli ⇧ Return to Top ⇧
Septic arthritis, Histoplasmosis ⇧ Return to Top ⇧
Septic arthritis, Lyme disease ⇧ Return to Top ⇧
Septic arthritis, Mycobacterium tuberculosis ⇧ Return to Top ⇧
Septic arthritis, pneumococcal ⇧ Return to Top ⇧
Septic arthritis, post-intraarticular injection ⇧ Return to Top ⇧
Septic arthritis, staphylococcal ⇧ Return to Top ⇧
Septic arthritis, streptococcal ⇧ Return to Top ⇧
Skin and Soft Tissues
Acne vulgaris ⇧ Return to Top ⇧
Acne rosacea ⇧ Return to Top ⇧
Anthrax, cutaneous ⇧ Return to Top ⇧
Bacillary angiomatosis ⇧ Return to Top ⇧
Bite wounds ⇧ Return to Top ⇧
Bubonic plague ⇧ Return to Top ⇧
Carbuncle ⇧ Return to Top ⇧
Cat scratch disease ⇧ Return to Top ⇧
Cellulitis ⇧ Return to Top ⇧
Ecthyma ⇧ Return to Top ⇧
Erysipelas ⇧ Return to Top ⇧
Erysipeloid ⇧ Return to Top ⇧
Erythrasma ⇧ Return to Top ⇧
Fournier gangrene ⇧ Return to Top ⇧
Furuncle ⇧ Return to Top ⇧
Gas gangrene ⇧ Return to Top ⇧
Glanders ⇧ Return to Top ⇧
Impetigo ⇧ Return to Top ⇧
Lyme disease, cutaneous ⇧ Return to Top ⇧
Mastitis ⇧ Return to Top ⇧
Necrotizing fasciitis ⇧ Return to Top ⇧
Pilonidal cyst ⇧ Return to Top ⇧
Pyomyositis ⇧ Return to Top ⇧
Seborrheic dermatitis ⇧ Return to Top ⇧
Skin and soft tissue infection in neutropenic fever ⇧ Return to Top ⇧
Skin and soft tissue infection in cellular immunodeficiency ⇧ Return to Top ⇧
Surgical site infection ⇧ Return to Top ⇧
Tularemia ⇧ Return to Top ⇧
Vascular insufficieny ulcer ⇧ Return to Top ⇧
Vibrio infection ⇧ Return to Top ⇧
Wound infection ⇧ Return to Top ⇧
Yaws ⇧ Return to Top ⇧
Systemic
Anaplasmosis ⇧ Return to Top ⇧
Babesiosis ⇧ Return to Top ⇧
Bartonella ⇧ Return to Top ⇧
Botulism ⇧ Return to Top ⇧
Boutonneuese fever ⇧ Return to Top ⇧
Brucellosis ⇧ Return to Top ⇧
Diptheria ⇧ Return to Top ⇧
Ehrlichiolsis ⇧ Return to Top ⇧
Febrile neutropenia, prophylaxis ⇧ Return to Top ⇧
Febrile neutropenia, treatment ⇧ Return to Top ⇧
Kawasaki syndrome ⇧ Return to Top ⇧
Leptospirosis ⇧ Return to Top ⇧
Lymphadenitis ⇧ Return to Top ⇧
Lymphangitis ⇧ Return to Top ⇧
Relapsing fever ⇧ Return to Top ⇧
Rocky Mountain spotted fever ⇧ Return to Top ⇧
Salmonella bacteremia ⇧ Return to Top ⇧
Sepsis ⇧ Return to Top ⇧
Staphylococcal toxic shock syndrome ⇧ Return to Top ⇧
Streptococcal toxic shock syndrome ⇧ Return to Top ⇧
Tetanus ⇧ Return to Top ⇧
Tularemia ⇧ Return to Top ⇧
Typhoid fever ⇧ Return to Top ⇧
Typhus, louse-borne ⇧ Return to Top ⇧
Typhus, murine ⇧ Return to Top ⇧
Typhus, scrub ⇧ Return to Top ⇧
References
- ↑ Baddour, Larry M.; Wilson, Walter R.; Bayer, Arnold S.; Fowler, Vance G.; Bolger, Ann F.; Levison, Matthew E.; Ferrieri, Patricia; Gerber, Michael A.; Tani, Lloyd Y.; Gewitz, Michael H.; Tong, David C.; Steckelberg, James M.; Baltimore, Robert S.; Shulman, Stanford T.; Burns, Jane C.; Falace, Donald A.; Newburger, Jane W.; Pallasch, Thomas J.; Takahashi, Masato; Taubert, Kathryn A.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America (2005-06-14). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): –394-434. doi:10.1161/CIRCULATIONAHA.105.165564. ISSN 1524-4539. PMID 15956145.
- ↑ Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.
- ↑ Wormser, Gary P.; Dattwyler, Raymond J.; Shapiro, Eugene D.; Halperin, John J.; Steere, Allen C.; Klempner, Mark S.; Krause, Peter J.; Bakken, Johan S.; Strle, Franc; Stanek, Gerold; Bockenstedt, Linda; Fish, Durland; Dumler, J. Stephen; Nadelman, Robert B. (2006-11-01). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 43 (9): 1089–1134. doi:10.1086/508667. ISSN 1537-6591. PMID 17029130.
- ↑ Wormser, Gary P.; Dattwyler, Raymond J.; Shapiro, Eugene D.; Halperin, John J.; Steere, Allen C.; Klempner, Mark S.; Krause, Peter J.; Bakken, Johan S.; Strle, Franc; Stanek, Gerold; Bockenstedt, Linda; Fish, Durland; Dumler, J. Stephen; Nadelman, Robert B. (2006-11-01). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 43 (9): 1089–1134. doi:10.1086/508667. ISSN 1537-6591. PMID 17029130.